Details
Rosulip Indications
- Primary Hypercholesterolemia (IIa type, including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when the effectiveness of diet or other non-drug methods (eg exercise, weight reduction) is inadequate.
- Homozygous familial hypercholesterolemia - as an adjunct to diet and other lipid-lowering treatments (eg LDL apheresis) or when such treatments are not acceptable.
Dosage & Admnistration
Before starting treatment, patients should appoint Rozulipom standard diet low in cholesterol, which must be observed throughout the course of treatment with rosuvastatin.
The dose should be individualized according to baseline levels of LDL cholesterol in the blood, treatment objectives and its effectiveness.
The daily dose of the drug is used once in any period of the day regardless of the meal.
The recommended initial dose for patients not previously taking statins or who are transferred to the administration of other inhibitors of HMG-CoA reductase inhibitors, should be 5 or 10 mg / day. To select the starting dose should be guided by the individual cholesterol level and take into account the risk of cardiovascular complications in the future, as well as the risk of adverse events. If necessary, the dose can be increased no sooner than 4 weeks.
Elderly patients
For patients over the age of 70 years, the recommended starting dose is 5 mg. In other cases, the dose adjustments depending on the age is required.
Contradictions
- sensitivity to the active agent or any of the excipients of the formulation;
- liver disease in the acute phase and the steady increase in transaminase levels of unknown origin is three times higher than normal;
- severe renal impairment (creatinine clearance <30 mL / min);
- myopathy;
- concurrent use of cyclosporin;
- pregnancy and breastfeeding;
- child age;
- women of reproductive age who are not using effective methods of contraception.
